1. Home
  2. BCDA vs AWX Comparison

BCDA vs AWX Comparison

Compare BCDA & AWX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • AWX
  • Stock Information
  • Founded
  • BCDA N/A
  • AWX 1998
  • Country
  • BCDA United States
  • AWX United States
  • Employees
  • BCDA N/A
  • AWX N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • AWX Environmental Services
  • Sector
  • BCDA Health Care
  • AWX Utilities
  • Exchange
  • BCDA Nasdaq
  • AWX Nasdaq
  • Market Cap
  • BCDA 9.4M
  • AWX 8.6M
  • IPO Year
  • BCDA N/A
  • AWX 1998
  • Fundamental
  • Price
  • BCDA $3.25
  • AWX $2.17
  • Analyst Decision
  • BCDA Strong Buy
  • AWX
  • Analyst Count
  • BCDA 1
  • AWX 0
  • Target Price
  • BCDA $60.00
  • AWX N/A
  • AVG Volume (30 Days)
  • BCDA 56.4K
  • AWX 4.3K
  • Earning Date
  • BCDA 08-07-2024
  • AWX 08-09-2024
  • Dividend Yield
  • BCDA N/A
  • AWX N/A
  • EPS Growth
  • BCDA N/A
  • AWX N/A
  • EPS
  • BCDA N/A
  • AWX N/A
  • Revenue
  • BCDA $468,000.00
  • AWX $80,999,000.00
  • Revenue This Year
  • BCDA N/A
  • AWX N/A
  • Revenue Next Year
  • BCDA $436.41
  • AWX N/A
  • P/E Ratio
  • BCDA N/A
  • AWX N/A
  • Revenue Growth
  • BCDA N/A
  • AWX N/A
  • 52 Week Low
  • BCDA $2.62
  • AWX $1.76
  • 52 Week High
  • BCDA $39.60
  • AWX $2.66
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 42.62
  • AWX 47.07
  • Support Level
  • BCDA $2.62
  • AWX $2.07
  • Resistance Level
  • BCDA $3.38
  • AWX $2.26
  • Average True Range (ATR)
  • BCDA 0.30
  • AWX 0.07
  • MACD
  • BCDA 0.11
  • AWX 0.01
  • Stochastic Oscillator
  • BCDA 82.88
  • AWX 32.26

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About AWX Avalon Holdings Corporation

Avalon Holdings Corp is a waste management company. The company provides waste management services to industrial, commercial, municipal, and governmental customers in selected northeastern and midwestern U.S. markets. The company has two operating segments. The Waste management services segment which is the key revenue driver, includes waste disposal services, captive landfill operations, and saltwater injection well operations. Its Golf and related operations segment includes management of golf courses and related clubhouses, a hotel, fitness centers, tennis courts, salon and spa services, dining, banquet, and conference facilities.

Share on Social Networks: